- Conditions
- Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS)
- Interventions
- S64315 once a week, S64315 twice a week
- Drug
- Lead sponsor
- Institut de Recherches Internationales Servier
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Acute Myeloid Leukaemia
- Interventions
- S 64315 (also referred as MIK665) and venetoclax
- Combination Product
- Lead sponsor
- Institut de Recherches Internationales Servier
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Houston, Texas